AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Protocol, Risk/Benefit Problems
Is anyone bothered by the study mentioned in "CDC Seeks to Expand Group B Strep Testing" (Feb. 1, 2002, p. 1)?
According to the article, the incidence of strep infection in those woman who were enrolled in a universal screening program was half that of women in a risk-based management program. Looking at the statistics mentioned, however, shows that 89% of patients identified by strep culture received penicillin, but only 60% met criteria for treatment with the risk-based approach.
Let me see if I get this straight: A 10% failure in administering antibiotics in one group and a 40% failure in the other group only makes a 50% difference in the incidence of strep infection? It does not sound like a problem with the risk-based approach; it sounds like a physician problem with following the protocol.
I am extremely concerned about the cost of cultures, antibiotics, and increased hospital care that universal screening is likely to lead to, as well as the potential for increased incidence of antibiotic resistance, yet none of these issues were really addressed in the article. Medicine must be practiced with a risk-versus-benefit assessment taken into account, yet this has not been done in this case.
Michael Gilliland, M.D.
Lake Jackson, Tex.
Source: HighBeam Research, Letters.